Horizon Europe European Union
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · European Union
Clinical trials for advancing innovative interventions for neurodegenerative diseases
Open
The EU's Horizon Europe programme expects to make 4 awards of €10 million each, from a total budget of €39.3 million. Applications close on 17 Feb 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.
- Deadline
- 17 Feb 2027 (in 94 days)
- Grant amount
- €10 million per project
- Total budget
- €39.3 million
- Funding rate
- 100% of eligible costs Standard rule for this programme; the call can differ.
- Total budget
- €39.3 million
- Expected awards
- 4
- Type of action
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Likely applicant types
- Companies, SMEs / start-ups, Non-profits, Universities & research, Public bodies From source categories or programme rules; the call decides.
- Funder
- Horizon Europe (HORIZON)
- Reference
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage
- Call
- HORIZON-HLTH-2027-02-two-stage
- Last checked
- 14 Nov 2026
Expected outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases.
• The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond.
• The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data.
Read the full text
• Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
• Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.
Scope
Neurodegenerative diseases are a high burden for patients, caregivers, health systems and society. Given the limitations with current therapeutic solutions, including that they primarily address symptoms rather than underlying causes and can have serious side effects, together with the increasing prevalence of neurodegenerative diseases in an aging population, there is a huge need to develop more innovative, safer and more effective therapeutic solutions for these diseases. To further enhance their safety and effectiveness, the therapeutic solution based on an active substance should be combined/complemented with another multidisciplinary approach (e.g. lifestyle changes, cognitive training, rehabilitation therapies). Together this innovative intervention should lead to an improved quality of life and reduce the societal impact of these diseases.
Rare neurodegenerative diseases are excluded [2] .
Read the full text
Proposals should address most of the following aspects:
• Perform rigorous early-stage [3] clinical trials into the safety and efficacy of the innovative interventions and their mode of administration, ensuring adequate cohorts/sample sizes with adequate representation of the patient population, including in terms of age, sex and ethnicity.
• Through the clinical trials and to the extent possible of additional studies, gain further insight into the potentially novel mechanism(s) of action of the innovative therapies and complementary approaches. This could entail analyses of imaging (e.g. MRI, ultrasound, nuclear imaging), as well as physiological, molecular, biochemical or omics signatures revealing potential perturbations prior to the intervention and recovery/improvement thereafter, and it could lead to the development of surrogate endpoints. This insight should open the path to more personalised interventions and approaches.
• Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence - AI [4] , wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disorder and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound.
• Utilise existing data, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles.
• Engage all relevant stakeholders (especially patients and patients’ representatives for the disease, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions, applying gender-sensitive and intersectional approaches.
• Advance research by leveraging already existing and emerging state-of-the-art research infrastructures (e.g. EuroBioImaging [5] , European Genomic Data Infrastructure [6] , ECRIN [7] , EATRIS [8] , EBRAINS [9] , BBMRI [10] , etc.), as well as results stemming from…
Who can apply
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Applicant categories are a starting point. The official call decides eligibility.
Topics
Brain research Clinical medicine Clinical neurology Clinical research Clinical trials Cognition (e.g. learning, memory, emotions, speech) Dementia Interventional clinical trials Molecular and cellular neuroscience Neurobiology Neurochemistry and neuropharmacology Neurodegenerative disorders Neuroinflammatory disorders Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) Neurology Neurosciences (including psychophysiology) Public health Interventions Neurodegeneration Neurodegenerative diseases
Timing
Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
How to apply
- Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
- Register each participating organisation in the Funding & Tenders Portal to get a PIC.
- Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
- Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
- Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | 17 February 2027 “Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).” | official data field | 15 Nov 2026 |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | €39.3 million | official data field | 15 Nov 2026 |
| Funding rate | 100% of eligible costs | programme standard rule | 15 Nov 2026 |
| Who can apply | Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule). | programme standard rule | 15 Nov 2026 |
| Where to apply | Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route. | read from the official text | 15 Nov 2026 |
Official sources
Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from Horizon Europe
Horizon Europe European Union
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe European Union
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe European Union
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe European Union
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…